Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Targetting deregulated signalling pathways in high-grade serous ovarian cancer: Defining therapeutic response and mechanisms of resistance

Ovarian cancer is the major cause of death from gynaecological cancer. Most patients present with advanced disease and die of their cancer. ..

Immune regulation, effector function and therapy

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

Anti-cancer activities of HDAC inhibitors

HDAC inhibitors (HDACi) are new chemotherapeutic drugs that kill tumors cells through a cell suicide process called apoptosis. We have now e..

Novel regulation of rDNA transcription by mTOR/S6K signalling

Increased cellular growth requires a number of important processes to occur, the most fundamental of which is protein synthesis. Successful ..

AKT regulation of growth and proliferation

Ribosome synthesis and function is critical for normal cell growth and division and hence this process is exquisitely regulated. Conversely,..

"Deregulation of ribosome signalling, synthesis and function during malignant transformation."

A major feature of tumour progression is accelerated cell growth and protein synthesis. Moreover, increased synthesis of ribosomes (the prot..

Regulation of ribosomal gene transcription by c-MYC during differentiation and lymphomagenesis.

A fundamental question in medical biology revolves around how cells respond to the demands to grow and produce proteins, particularly in the..

New therapies for MYC-associated cancers

This proposal will evaluate a new strategy for treating cancers associated with the cancer causing gene MYC. Globally there are more than 1 ..

ONCOGENIC SIGNALING AND CANCER THERAPY

Central to improving the management of patients with cancer is an understanding of the molecular drivers of cancer. Based on our fundamental..

NOVEL APPROACHES TO TREAT REFRACTORY HAEMATOLOGICAL MALIGNANCIES